{"summary": "Wallstreetbets repost of the same EXEL short thesis: FDA full approval of Handa's cabozantinib generic is unpriced by Wall Street.", "reason": "Author provides a specific asset, directional thesis, and fundamental catalyst regarding generic drug approval.", "ideas": [{"symbol": "EXEL", "direction": "short", "thesis": "Author claims Exelixis relies on cabozantinib (CABOMETYX) for essentially all revenue (~$2B/yr) and that the FDA gave full approval to Handa's generic on 9/3, meaning patent disputes are resolved and the cheaper drug can sell in the US immediately. He notes EXEL voluntarily withdrew its Delaware suit against Handa on 8/31 and its FDA citizen petition failed, so the recent ~20% rally on patent-win headlines is misplaced. The catalyst is Wall Street connecting these dots, since the approval news was only in Taiwanese sources; main risk is that the market has already priced the generic or its launch is delayed.", "thesis_short": "EXEL short on unpriced Handa generic approval", "quote": "The key is: I think Wall St has genuinely not yet put two and two together, that this company's main source of revenue just got handed a major L by a cheaper generic, likely launching within days.", "confidence": 0.8, "sentiment": -0.8, "timeframe": "days"}], "model": "gemini-3.1-flash-lite", "verified": true, "extraction_model": "deepseek-v4-flash"}
This Reddit post, published September 09, 2026, features u/Biostatrat discussing EXEL. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: u/Biostatrat · Tickers: EXEL